Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor

High Blood Pressure & Cardiovascular Prevention - Tập 25 Số 4 - Trang 345-354 - 2018
Marco Grasso1, Marco Boscaro1, Carla Scaroni1, Filippo Ceccato1
1Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. https://doi.org/10.1093/eurheartj/eht151 .

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–54. https://doi.org/10.1093/eurheartj/eht534 .

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. https://doi.org/10.1161/CIRCULATIONAHA.108.189141 .

El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7(June):1–10. https://doi.org/10.3389/fendo.2016.00072 .

Ceccato F, Scaroni C, Boscaro M. The adrenal glands. In: Belfiore A, LeRoith D, editors. Principles of endocrinology and hormone action, Chap 15. Switzerland: Springer; 2016. p. 387–421. https://doi.org/10.1007/978-3-319-27318-1_16-1 .

Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4 .

Cicala MV, Mantero F. Hypertension in Cushing’s Syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92(1):44–9. https://doi.org/10.1159/000314315 .

Isidori A, Graziadio C, Paragliola R, et al. The hypertension of Cushingʼs syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens. 2015;33(1):44–60. https://doi.org/10.1097/HJH.0000000000000415 .

Eisenhofer G. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49. https://doi.org/10.1124/pr.56.3.1 .

Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab. 2017;32(2):152. https://doi.org/10.3803/EnM.2017.32.2.152 .

Funder J, Carey R, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061 .

Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40. https://doi.org/10.1210/jc.2008-0125 .

Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. https://doi.org/10.1210/jc.2014-1498 .

Sabbadin C, Fallo F. Hyperaldosteronism: screening and diagnostic tests. High Blood Press Cardiovasc Prev. 2016;23(2):69–72. https://doi.org/10.1007/s40292-016-0136-5 .

Williams TA, Reincke M. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19–29. https://doi.org/10.1530/EJE-17-0990 .

Cicala MV, Mantero F. Primary aldosteronism: what consensus for the diagnosis. Best Pract Res Clin Endocrinol Metab. 2010;24(6):915–21. https://doi.org/10.1016/j.beem.2010.10.007 .

Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9. https://doi.org/10.1210/jc.2005-1733 .

Fischer E, Adolf C, Pallauf A, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98(6):2513–20. https://doi.org/10.1210/jc.2012-3934 .

Hanslik G, Wallaschofski H, Dietz A, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015;173(5):665–75. https://doi.org/10.1530/EJE-15-0450 .

Beuschlein F, Mulatero P, Asbach E, et al. The SPARTACUS Trial: controversies and unresolved issues. Horm Metab Res. 2017;49(12):936–42. https://doi.org/10.1055/s-0043-120524 .

Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147(7):1289–93. http://www.ncbi.nlm.nih.gov/pubmed/3606286 .

Anderson GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609–15. http://www.ncbi.nlm.nih.gov/pubmed/7930562 .

Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2018;6(3):249–52. https://doi.org/10.4158/ep.6.3.249 .

Wyszyńska T, Cichocka E, Wieteska-Klimczak A, Jobs K, Januszewicz P. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr. 1992;81(3):244–46. http://www.ncbi.nlm.nih.gov/pubmed/1511199 .

Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44. https://doi.org/10.1210/jcem.85.2.6372 .

Lafont M, Fagour C, Haissaguerre M, et al. Per-operative hemodynamic instability in normotensive patients with incidentally discovered pheochromocytomas. J Clin Endocrinol Metab. 2015;100(2):417–21. https://doi.org/10.1210/jc.2014-2998 .

Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G34. https://doi.org/10.1530/EJE-16-0467 .

Shimon I. Screening for Cushing’s syndrome: is it worthwhile? Pituitary. 2015;18(2):201–5. https://doi.org/10.1007/s11102-015-0634-9 .

Ceccato F, Boscaro M. Cushing’s syndrome: screening and diagnosis. High Blood Press Cardiovasc Prev. 2016;23(3):209–15. https://doi.org/10.1007/s40292-016-0153-4 .

Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121–31. https://doi.org/10.1210/jc.2009-0612 .

Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98(6):2277–84. https://doi.org/10.1210/jc.2012-3582 .

Hirsch D, Shimon I, Manisterski Y, et al. Cushing’s syndrome: comparison between Cushing’s disease and adrenal Cushing’s. Endocrine. 2018. https://doi.org/10.1007/s12020-018-1709-y .

Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202. https://doi.org/10.1291/hypres.27.193 .

Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998;19(5):647–72. https://doi.org/10.1210/edrv.19.5.0346 .

Tirabassi G, Boscaro M, Arnaldi G. Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine. 2014;46(3):370–86. https://doi.org/10.1007/s12020-013-0112-y .

Ceccato F, Antonelli G, Barbot M, et al. The diagnostic performance of urinary free cortisol is better than the cortisol: cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC–MS/MS method in routine clinical practice. Eur J Endocrinol. 2014;171(1):1–7. https://doi.org/10.1530/eje-14-0061 .

Ceccato F, Barbot M, Zilio M, et al. Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC–MS/MS. J Clin Endocrinol Metab. 2015;100(10):3856–61. https://doi.org/10.1210/jc.2015-2507 .

Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC–MS/MS. J Endocrinol Investig. 2017;40(7):753–60. https://doi.org/10.1007/s40618-017-0644-8 .

Raff H. Cushing’s syndrome: diagnosis and surveillance using salivary cortisol. Pituitary. 2012;15(1):64–70. https://doi.org/10.1007/s11102-011-0333-0 .

Ceccato F, Barbot M, Zilio M, et al. Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur J Endocrinol. 2013;169(1):31–6. https://doi.org/10.1530/eje-13-0159 .

Deutschbein T, Broecker-Preuss M, Flitsch J, et al. Salivary cortisol as a diagnostic tool for Cushing’s syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol. 2012;166(4):613. https://doi.org/10.1530/EJE-11-0945 .

Ceccato F, Marcelli G, Martino M, et al. The diagnostic accuracy of increased late night salivary cortisol for Cushing’s syndrome: a real-life prospective study. J Endocrinol Investig. 2018. https://doi.org/10.1007/s40618-018-0921-1 .

Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92(11):4123–9. https://doi.org/10.1210/jc.2007-0596 .

Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553–62. https://doi.org/10.1210/jc.2008-0139 .

Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(12):4851–9. https://doi.org/10.1210/jc.2009-1500 .

Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31. https://doi.org/10.1210/jc.2015-1818 .

Ceccato F, Barbot M, Zilio M, Albiger N, Mantero F, Scaroni C. Therapeutic strategies for Cushing’s syndrome: an update. Expert Opin Orphan Drugs. 2015;3(1):45–56. https://doi.org/10.1517/21678707.2015.991714 .